FDA AI Deregulation: What Medical Device Founders Need to Know

← Back to All Insights

The Trump administration's January 2026 executive orders signal the most significant shift in FDA oversight of digital health since the 21st Century Cures Act. For medical device founders and investors, understanding what's actually changing—versus what's political posturing—is critical for strategic planning.

As a physician who reviews AI medical devices for investors, I'm seeing both genuine opportunities and dangerous misconceptions emerge from these policy shifts.

What's Actually Changing

The executive orders direct FDA to "reduce regulatory burden" on AI and wearable devices, but the practical implications are nuanced. Here's what we know so far:

1. Enforcement Discretion Expansion

FDA has historically exercised enforcement discretion for low-risk wellness devices. The new guidance expands this to include certain AI-enabled general wellness products that make limited claims. Key changes include:

• Broader definition of "general wellness" for AI products
• Streamlined pathways for AI devices with predetermined change control plans (PCCPs)
• Reduced documentation requirements for certain algorithm updates
• Faster breakthrough device designation reviews for AI applications

2. Wearable Device Reclassification

Several categories of wearables are being considered for reclassification from Class II to Class I, potentially eliminating 510(k) requirements for:

• Continuous glucose monitors for general wellness (non-diabetic) use
• Heart rate variability monitors without diagnostic claims
• Sleep tracking devices without apnea detection claims
• Activity monitors with basic physiological measurements

What's NOT Changing

Despite the rhetoric, several core FDA requirements remain firmly in place:

• Clinical Decision Support: Software that provides patient-specific diagnostic or treatment recommendations still requires clearance
• High-Risk AI: Devices making autonomous clinical decisions (e.g., insulin dosing, arrhythmia detection with therapy) maintain current oversight
• Quality System Regulations: QSR/cGMP requirements remain unchanged for all cleared devices
• Post-Market Surveillance: Adverse event reporting and recall obligations continue
• Predetermined Change Control Plans: Still required; just potentially more flexible

Strategic Implications for Medical Device Companies

For Early-Stage Startups

The deregulatory environment creates a strategic choice:

Strategy	Pros	Cons
Go Wellness First Launch with limited claims, expand later	Faster time to market Lower regulatory costs Generate real-world data	Limited reimbursement Harder to pivot to clinical claims Competitive moat questions
Pursue Full Clearance 510(k) or De Novo from the start	Defensible market position Reimbursement pathways Clinical credibility	Longer timeline (12-24 months) Higher upfront costs May be "overbuilt" for market
Hybrid Approach Wellness launch with parallel regulatory submission	Revenue while pursuing clearance Real-world evidence generation Flexibility	Complex regulatory strategy Labeling constraints Higher total cost

For Growth-Stage Companies

Companies with existing FDA clearances should consider:

• Expanding PCCPs: Review whether your predetermined change control plan can be broadened under new guidance
• Adjacent Wellness Products: Consider "flanker" products with wellness positioning that don't require new submissions
• International Strategy: EU MDR remains stringent; don't assume US deregulation translates globally

For Investors

Due diligence should now include:

• Assessment of regulatory strategy resilience to policy reversals
• Evaluation of whether "wellness" positioning limits exit opportunities
• Understanding of how deregulation affects competitive moats
• International regulatory pathway viability

The Clinical Perspective

From a physician's standpoint, I have mixed feelings about these changes. On one hand, regulatory burden has genuinely slowed beneficial innovations reaching patients. On the other hand, I've seen firsthand how unvalidated AI can mislead clinical decisions.

The core question isn't whether FDA should regulate less—it's whether the market can adequately sort good AI from bad AI without regulatory gatekeeping. History suggests caution: the supplement industry shows what happens when FDA takes a hands-off approach.

What to Watch

Several developments in the coming months will clarify the practical impact:

• Q2 2026: FDA guidance document on AI/ML device modifications expected
• Ongoing: Congressional oversight hearings on FDA enforcement priorities
• 2026: First major adverse events from uncleared AI wellness devices (if they occur) could trigger reversal
• 2027-2028: Potential administration change could reverse executive orders